[HTML][HTML] Epidermal growth factor receptor inhibition in lung cancer: status 2012
… Lung cancer is the most common cause of cancer deaths. … However, with the understanding
of lung cancer biology, and … non–small-cell lung cancer (NSCLC). Epidermal growth factor …
of lung cancer biology, and … non–small-cell lung cancer (NSCLC). Epidermal growth factor …
Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer
M Tiseo, M Loprevite, A Ardizzoni - … Chemistry-Anti-Cancer …, 2004 - ingentaconnect.com
… , already registered for the treatment of advanced breast cancer and currently under
investigation in non-small-cell lung cancer [20]. In lung cancer, growth inhibition with trastuzumab …
investigation in non-small-cell lung cancer [20]. In lung cancer, growth inhibition with trastuzumab …
Epidermal growth factor receptor inhibitors in the treatment of non–small-cell lung cancer
G Giaccone - Journal of Clinical Oncology, 2005 - ascopubs.org
… Epidermal Growth Factor Receptor in Non–Small-cell Lung Cancer Lung cancer develops
… and genetic defects have been identified in lung cancer, but a clear understanding of the …
… and genetic defects have been identified in lung cancer, but a clear understanding of the …
Epidermal growth factor receptor inhibitors in development for the treatment of non–small cell lung cancer
JV Heymach, M Nilsson, G Blumenschein… - Clinical cancer …, 2006 - AACR
… non–small cell lung cancer and other types of solid tumors. A number of newer inhibitors are
… of activity or mechanisms of receptor inhibition. These include monoclonal antibodies, such …
… of activity or mechanisms of receptor inhibition. These include monoclonal antibodies, such …
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
… Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic
strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer. (Cancer …
strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer. (Cancer …
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
AF Gazdar - Cancer and Metastasis Reviews, 2010 - Springer
… Several strategies for inhibition of EGFR, including tyrosine kinase inhibition, have been
developed for treatment of human cancers, including lung cancer. EGFR is frequently …
developed for treatment of human cancers, including lung cancer. EGFR is frequently …
Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non–small-cell lung cancer
… Worldwide, the majority of patients with advanced non–small-cell lung cancer (… receptor
(EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors …
(EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors …
The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo
OE Pardo, J Latigo, RE Jeffery, E Nye, R Poulsom… - Cancer research, 2009 - AACR
… of the inhibitor. Crucially, … inhibition of FGFR kinase activity, while improving response
to classic therapeutic agents, could be efficient as a monotherapy for a subset of lung cancer …
to classic therapeutic agents, could be efficient as a monotherapy for a subset of lung cancer …
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
SS Sridhar, L Seymour, FA Shepherd - The lancet oncology, 2003 - thelancet.com
… -cell lung cancer (NSCLC) is the leading cause of cancer-related … In particular, the epidermal
growth-factor receptor superfamily … Several selective inhibitors of this family of receptors are …
growth-factor receptor superfamily … Several selective inhibitors of this family of receptors are …
Biomarkers of response to epidermal growth factor receptor inhibitors in non–small-cell lung cancer working group: standardization for use in the clinical trial setting
DA Eberhard, G Giaccone, BE Johnson - Journal of Clinical Oncology, 2008 - ascopubs.org
… of lung cancers but not in breast cancers. Trastuzumab, an MoAb directed against the HER-2
protein, inhibits the growth of HER2-amplified/HER-2–overexpressing breast cancer cells …
protein, inhibits the growth of HER2-amplified/HER-2–overexpressing breast cancer cells …
相关搜索
- cell lung cancer receptor antagonists
- non-small cell lung cancer
- lung cancer growth factor
- lung cancer cell lines
- cell lung cancer patients
- receptor tyrosine kinase inhibitors lung cancers
- cell lung cancer egfr inhibitors
- epidermal growth factor receptor inhibitors
- receptor inhibitors cancer therapeutics
- small cell lung cancer growth factor
- lung cancer epidermal growth factor receptor
- cell lung cancer growth factor receptor
- small cell lung cancer receptor mutations
- breast cancer receptor inhibitors
- lung cancer receptor blockers
- lung cancer receptor inhibitors docking